Infection Biology Lab, Instituto Superior de Investigaciones Biológicas (INSIBIO), CONICET-UNT, Tucumán, Argentina.
Facultad de Medicina, Universidad Nacional de Tucumán (UNT), Tucumán, Argentina.
Front Immunol. 2020 Jan 23;11:15. doi: 10.3389/fimmu.2020.00015. eCollection 2020.
Non-viable lactic acid bacteria (LAB) have been proposed as antigen delivery platforms called bacterium-like particles (BLPs). Most studies have been performed with -derived BLPs where multiple antigens were attached to the peptidoglycan surface and used to successfully induce specific immune responses. It is well-established that the immunomodulatory properties of LAB are strain dependent and therefore, the BLPs derived from each individual strain could have different adjuvant capacities. In this work, we obtained BLPs from immunomodulatory (immunobiotics) and non-immunomodulatory and strains and comparatively evaluated their ability to improve the intestinal and systemic immune responses elicited by an attenuated rotavirus vaccine. Results demonstrated that orally administered BLPs from non-immunomodulatory strains did not induce significant changes in the immune response triggered by rotavirus vaccine in mice. On the contrary, BLPs derived from immunobiotic lactobacilli were able to improve the levels of anti-rotavirus intestinal IgA and serum IgG, the numbers of CD24B220 B and CD4 T cells in Peyer's patches and spleen as well as the production of IFN-γ by immune cells. Interestingly, among immunobiotics-derived BLPs, those obtained from CRL1505 and IBL027 enhanced more efficiently the intestinal and systemic humoral immune responses when compared to BLPs from other immunobiotic bacteria. The findings of this work indicate that it is necessary to perform an appropriate selection of BLPs in order to find those with the most efficient adjuvant properties. We propose the term Immunobiotic-like particles (IBLPs) for the BLPs derived from CRL1505 and IBL027 strains that are an excellent alternative for the development of mucosal vaccines.
非活性乳酸菌 (LAB) 已被提议作为称为细菌样颗粒 (BLPs) 的抗原递呈平台。大多数研究都是使用 - 衍生的 BLPs 进行的，其中多个抗原附着在肽聚糖表面上，并成功地诱导了特异性免疫反应。众所周知，LAB 的免疫调节特性取决于菌株，因此，源自每个单独菌株的 BLPs 可能具有不同的佐剂能力。在这项工作中，我们从免疫调节 (免疫生物) 和非免疫调节 的 和 菌株中获得 BLPs，并比较评估了它们改善减毒轮状病毒疫苗引起的肠道和全身免疫反应的能力。结果表明，非免疫调节菌株的口服 BLPs 不会引起轮状病毒疫苗在小鼠中引发的免疫反应发生显著变化。相反，来自免疫生物乳杆菌的 BLPs 能够提高抗轮状病毒肠道 IgA 和血清 IgG 的水平、派尔氏斑和脾脏中 CD24B220 B 和 CD4 T 细胞的数量以及免疫细胞产生的 IFN-γ。有趣的是，在免疫生物衍生的 BLPs 中，与来自其他免疫生物细菌的 BLPs 相比，来自 CRL1505 和 IBL027 的 BLPs 更有效地增强了肠道和全身体液免疫反应。这项工作的结果表明，有必要对 BLPs 进行适当的选择，以找到具有最有效佐剂特性的 BLPs。我们提出了免疫生物样颗粒 (IBLP) 的术语，用于源自 CRL1505 和 IBL027 菌株的 BLPs，它们是粘膜疫苗开发的绝佳选择。
